Cargando…
Use of firocoxib for the treatment of equine osteoarthritis
This review presents the pathogenesis and medical treatment of equine osteoarthritis (OA), focusing on firocoxib. Inhibition of prostaglandin E(2) remains a fundamental treatment for decreasing clinical symptoms (ie, pain and lameness) associated with OA in horses. Nonsteroidal anti-inflammatory dru...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7337192/ https://www.ncbi.nlm.nih.gov/pubmed/32670856 http://dx.doi.org/10.2147/VMRR.S70207 |
_version_ | 1783554461465051136 |
---|---|
author | Donnell, Josh R Frisbie, David D |
author_facet | Donnell, Josh R Frisbie, David D |
author_sort | Donnell, Josh R |
collection | PubMed |
description | This review presents the pathogenesis and medical treatment of equine osteoarthritis (OA), focusing on firocoxib. Inhibition of prostaglandin E(2) remains a fundamental treatment for decreasing clinical symptoms (ie, pain and lameness) associated with OA in horses. Nonsteroidal anti-inflammatory drugs (NSAIDs), which inhibit the production of prostaglandin E(2) from the arachidonic acid pathway, continue to be a mainstay for the clinical treatment of OA. Firocoxib is a cyclooxygenase (COX)-2-preferential NSAID that has been shown to be safe and to have a 70% oral bioavailability in the horse. Three clinical reports identified symptom-modifying effects (reduction in pain and/or lameness) in horses with OA administered the once-daily recommended dose (0.1 mg/kg) of oral firocoxib following 7 days of administration. Other reports have suggested that a one-time loading dose (0.3 mg/kg) of firocoxib provides an earlier (1–3 days) onset of action compared to the recommended dose. It is noteworthy that OA disease-modifying effects have been reported in horses for other COX-2-preferential NSAIDs (meloxicam and carprofen), but have not been attributed to firocoxib due to a lack of investigation to date. |
format | Online Article Text |
id | pubmed-7337192 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-73371922020-07-14 Use of firocoxib for the treatment of equine osteoarthritis Donnell, Josh R Frisbie, David D Vet Med (Auckl) Review This review presents the pathogenesis and medical treatment of equine osteoarthritis (OA), focusing on firocoxib. Inhibition of prostaglandin E(2) remains a fundamental treatment for decreasing clinical symptoms (ie, pain and lameness) associated with OA in horses. Nonsteroidal anti-inflammatory drugs (NSAIDs), which inhibit the production of prostaglandin E(2) from the arachidonic acid pathway, continue to be a mainstay for the clinical treatment of OA. Firocoxib is a cyclooxygenase (COX)-2-preferential NSAID that has been shown to be safe and to have a 70% oral bioavailability in the horse. Three clinical reports identified symptom-modifying effects (reduction in pain and/or lameness) in horses with OA administered the once-daily recommended dose (0.1 mg/kg) of oral firocoxib following 7 days of administration. Other reports have suggested that a one-time loading dose (0.3 mg/kg) of firocoxib provides an earlier (1–3 days) onset of action compared to the recommended dose. It is noteworthy that OA disease-modifying effects have been reported in horses for other COX-2-preferential NSAIDs (meloxicam and carprofen), but have not been attributed to firocoxib due to a lack of investigation to date. Dove 2014-11-04 /pmc/articles/PMC7337192/ /pubmed/32670856 http://dx.doi.org/10.2147/VMRR.S70207 Text en © 2014 Donnell and Frisbie http://creativecommons.org/licenses/by-nc/3.0/ This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php |
spellingShingle | Review Donnell, Josh R Frisbie, David D Use of firocoxib for the treatment of equine osteoarthritis |
title | Use of firocoxib for the treatment of equine osteoarthritis |
title_full | Use of firocoxib for the treatment of equine osteoarthritis |
title_fullStr | Use of firocoxib for the treatment of equine osteoarthritis |
title_full_unstemmed | Use of firocoxib for the treatment of equine osteoarthritis |
title_short | Use of firocoxib for the treatment of equine osteoarthritis |
title_sort | use of firocoxib for the treatment of equine osteoarthritis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7337192/ https://www.ncbi.nlm.nih.gov/pubmed/32670856 http://dx.doi.org/10.2147/VMRR.S70207 |
work_keys_str_mv | AT donnelljoshr useoffirocoxibforthetreatmentofequineosteoarthritis AT frisbiedavidd useoffirocoxibforthetreatmentofequineosteoarthritis |